Medical
Bujagouni Swapna; Kaneez Fathima; Hifsa Muwayyad; Madeeha Khanam; Syeda Salma; Surabhi Harsha; Numair Gayas
Abstract
Chronic kidney disease (CKD) is on the rise around the world and is strongly linked with the incidence of cardiovascular disease (CVD). This six-month observational study was conducted in the nephrology division of a 300-bed, multi-specialty tertiary care teaching hospital. A total of 90 prescriptions ...
Read More
Chronic kidney disease (CKD) is on the rise around the world and is strongly linked with the incidence of cardiovascular disease (CVD). This six-month observational study was conducted in the nephrology division of a 300-bed, multi-specialty tertiary care teaching hospital. A total of 90 prescriptions written for inpatients and outpatients in the nephrology ward are considered based on the inclusion criteria. Patient case sheets, patient questionnaires and interviews, biomedical and radiological reports, and the medication regimen chart are the primary means of data gathering. In this study, we identified the patient's age, hypertension, lipid abnormalities, male gender, cigarette smoking, and family history as traditional risk factors for both CVD and CKD. Nearly 40% of 90 individuals had a high risk of CVD, followed by 25 with intermediate risk, 19 with borderline risk, and 6 with low risk. We further conclude that successful CKD and CVD therapy requires good glycemic control, anti-hypertensive medicine, and hypolipidemic medication. Diabetes patients received SGLT-2 inhibitors, which improve CKD and CVD. The development of chronic kidney disease to stages 4 and 5 is slowed by anti-hypertensive medication, particularly with renin-angiotensin-aldosterone system inhibitors such as angiotensin-receptor blockers and angiotensin-converting enzyme (ACE) inhibitors. Patients with persistent hypertension, albuminuria, or heart failure with a poor ejection fraction benefit from treatment with aldosterone receptor antagonists. People with chronic kidney disease benefit from low-dose aspirin for secondary prevention of cardiovascular disease. Despite medication advancements, high blood pressure (BP) patients need a customised and evidence-based management plan to control BP, minimise CVD risk, and delay CKD progression. Early CKD treatment is essential for preventing the progression of both CKD and CVD.
Medical
Koteswari Poluri; Bujagouni Swapna; Vatte Jyothsna; Kaneez Fathima; Omamah Afreen; Shaheroz Jabeen; Sumera Sultana
Abstract
The occurrence of an ischemic stroke arises from the unfortunate circumstance in which a blood vessel becomes impeded or obstructed, resulting from the presence of a clot, atherosclerosis, or the narrowing of arteries. The neurology department of a 300-bed, multi-specialty tertiary teaching hospital ...
Read More
The occurrence of an ischemic stroke arises from the unfortunate circumstance in which a blood vessel becomes impeded or obstructed, resulting from the presence of a clot, atherosclerosis, or the narrowing of arteries. The neurology department of a 300-bed, multi-specialty tertiary teaching hospital was the site of this six-month observational study. Prescriptions for both inpatients and outpatients in the neurology unit, totalling 90, are considered according to the inclusion criteria. Patient case sheets, questionnaires, interviews, biomedical and radiological reports, and drug regimen charts are the main data sources. Acute ischemic stroke (AIS) patients are more prevalent in the over-60 age group than in the 20–35 age group. The information obtained indicates that male patients have greater effects than female ones. Furthermore, our research indicates that AIS is more common in obese and overweight people. One of the main risk factors for developing AIS is alcohol drinking, tobacco chewing, and smoking, which affect most AIS patients. Treatment options for acute ischemic stroke (AIS) include intravenous thrombolytic therapy (IVT), anti-platelet therapy, anticoagulant therapy, and adjuvant therapies using statins and drugs based on the comorbidities of the patients. This research highlights that individuals with AIS have shown higher progress when physical rehabilitation is combined with intravenous thrombolytic treatment (IVT) for patients with comorbidities. We found that the individuals who continued taking their medicine and therapy after their discharge from the hospital had better motor strength than those who stopped. Our study concludes that the integration of pharmacotherapy with physical rehabilitation yielded significant enhancements in the functional capacity of individuals affected by stroke.
)
)